Who are Keveyis's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sodium Nitrite, Syprine, Plasma-Lyte A In Plastic Container, Ethamide, Sulfamylon, Avc.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dichlorphenamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Keveyis — Competitive Intelligence Brief

Keveyis (DICHLORPHENAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic Anhydrase Inhibitor [EPC]. Area: Ophthalmology.

marketed Carbonic Anhydrase Inhibitor [EPC] Carbonic anhydrase 1 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Keveyis (DICHLORPHENAMIDE). Keveyis works by inhibiting the enzyme carbonic anhydrase, which is involved in the production of aqueous humor in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Keveyis TARGET	DICHLORPHENAMIDE		marketed	Carbonic Anhydrase Inhibitor [EPC]	Carbonic anhydrase 1	1958-01-01
Sodium Nitrite	SODIUM NITRITE	Hope Pharms	marketed	sodium nitrite	Carbonic anhydrase 1	2011-01-01
Syprine	TRIENTINE	Bausch Health	marketed	Copper Chelator	Carbonic anhydrase 14	1985-01-01
Plasma-Lyte A In Plastic Container	Sodium Acetate	Pfizer	marketed	sodium acetate	Carbonic anhydrase 1, Carbonic anhydrase	1983-01-01
Ethamide	ETHOXZOLAMIDE	Pfizer	marketed	ethoxzolamide	Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13	1982-01-01
Sulfamylon	MAFENIDE	Rising	marketed	Methylated Sulfonamide Antibacterial	Carbonic anhydrase 12	1969-01-01
Avc	SULFANILAMIDE	Pharmobedient	marketed	sulfanilamide	Carbonic anhydrase 13	1965-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic Anhydrase Inhibitor [EPC] class)

· 1 drug in this class
Novartis · 1 drug in this class
Teva · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Keveyis — Competitive Intelligence Brief. https://druglandscape.com/ci/dichlorphenamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab